Furthermore, the identification of certain genetic defects in MM patients such as t(4;14) and UTX/KDM6A-deletion that pre-dispose to EZH2 inhibition may provide more effective and personalized treatment by using EZH2 inhibitors. This evidence concerns the gene EZH2 and Miyoshi myopathy.